ÖZ
Amaç
İlerlemiş akciğer kanseri hastalarının çoğunda, kemoradyoterapiyle orta düzeyde bir cevap alınsa da sonuçlar yüz güldürücü değildir. Akciğer kanserinde, lenfosit yüzdeleri ve interlökin-6 (IL-6) sitokin düzeylerinin yaşam oranları ile anlamlı düzeyde korelasyon gösterdiği bildirilmiştir. Bu çalışmada, lenfosit yüzdeleri ve IL-6 düzeylerinin genel sağkalım ve progresyonsuz sağkalım üzerine etkisini araştırdık.
Yöntemler
Çalışmaya akciğer kanseri tanısı almış ve radyoterapi görmüş 142 hasta dahil edildi. Hastalar cinsiyet, yaş, klinik evre, Eastern Cooperative Oncology Group performans durumu, patoloji ve radyoterapi öncesi lenfosit yüzdeleri ve IL-6 sitokin seviyelerine göre incelendi. Sonuçlar ayrıca radyoterapi dozu, tedavi bölgeleri ve yanıt oranlarına göre analiz edildi.
Bulgular
Lenfosit yüzdesi >%15 olan hastalar lenfosit yüzdesi ≤%15 olan hastalarla karşılaştırıldığında, medyan genel sağ kalım sırasıyla 18 ay ve 7 ay, progresyonsuz sağ kalım sırasıyla 17 ve 5 ay olarak bulundu ve medyan genel sağ kalım ve progresyonsuz sağ kalım lenfosit yüzdesi >%15 olanlarda anlamlı şekilde daha yüksekti (p=0,007 ve p=0,006). IL-6 ≤7 pg/mL olan hastalar >7 pg/mL olan hastalarla karşılaştırıldığında, medyan genel sağ kalım 14 ve 7 ay, progresyonsuz sağ kalım 9 ve 4 ay idi ve medyan genel sağ kalım ve progresyonsuz sağ kalım IL-6 ≤7 pg/mL olan hastalarda anlamlı derecede daha yüksekti (p=0,011 ve p=0,01).
Sonuç
İlerlemiş akciğer kanseri hastalarında, radyoterapi öncesi lenfosit sayımı ve IL-6 düzeyleri önemli prognostik biyobelirteçlerdir ve bu testler hasta takibinde ve farklı tedavi stratejileri geliştirmek için kullanılabilir.
Anahtar Kelimeler:
Kanserde IL-6, kanserde lenfosit, kanserde inflamasyon, hematotoksisitede radyasyon
Kaynaklar
1
Ohashi K, Nishito Y, Fukuda H, Sadahiro R, Yoshida Y, Watanabe SI, et al. Neutrophil-to-lymphocyte ratio is a prognostic factor reflecting immune condition of tumor microenvironment in squamous cell lung cancer. Sci Rep. 2024;14:429.
2
Relli V, Trerotola M, Guerra E, Alberti S. Abandoning the notion of non-small cell lung cancer. Trends Mol Med. 2019;25:585-94.
3
de Sousa VML, Carvalho L. Heterogeneity in lung cancer. Pathobiology. 2018;85:96-107.
4
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
5
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
6
Gail MH, Eagan RT, Feld R, Ginsberg R, Goodell B, Hill L, et al. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group. Cancer. 1984;54:1802-13.
7
Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379-86.
8
Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181-90.
9
Lin X, Li W, Lai J, Okazaki M, Sugimoto S, Yamamoto S, et al. Five-year update on the mouse model of orthotopic lung transplantation: Scientific uses, tricks of the trade, and tips for success. J Thorac Dis. 2012;4:247-58.
10
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565-70.
11
Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6:149-63.
12
Balmanoukian A, Ye X, Herman J, Laheru D, Grossman SA. The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. Cancer Invest. 2012;30:571-6.
13
Frey B, Rubner Y, Wunderlich R, Weiss EM, Pockley AG, Fietkau R, et al. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies. Curr Med Chem. 2012;19:1751-64.
14
Yang H, Jin T, Li M, Xue J, Lu B. Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges. Precis Clin Med. 2019;2:57-70.
15
Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017;8:1-20.
16
Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91:181-4.
17
Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19:217-24.
18
Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI, et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol. 2011;18:3362-9.
19
Gu XB, Tian T, Tian XJ, Zhang XJ. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep. 2015;5:12493.
20
Chen Y, Wang W, Zhang X, Yu X, Xi K, Wen Y, et al. Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer. Cancer Manag Res. 2018;10:5411-22.
21
Li B, Zhou P, Liu Y, Wei H, Yang X, Chen T, et al. Platelet-to-lymphocyte ratio in advanced cancer: review and meta-analysis. Clin Chim Acta. 2018;483:48-56.
22
Pike LRG, Bang A, Mahal BA, Taylor A, Krishnan M, Spektor A, et al. The impact of radiation therapy on lymphocyte count and survival in metastatic cancer patients receiving pd-1 immune checkpoint inhibitors. Int J Radiat Oncol Biol Phys. 2019;103:142-51.
23
Gu X, Ma C, Yuan D, Song Y. Circulating soluble intercellular adhesion molecule-1 in lung cancer: a systematic review. Transl Lung Cancer Res. 2012;1:36-44.
24
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
25
Colevas A, Setser A. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. Journal of Clinical Oncology. 2004;22:6098.
26
Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. Lung cancer susceptibility: are we on our way to identifying a high-risk group? Future Oncol. 2007;3:617-27.
27
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436-44.
28
Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383-91.
29
Nishijima TF, Muss HB, Shachar SS, Tamura K, Takamatsu Y. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis. Cancer Treat Rev. 2015;41:971-8.
30
Mei Z, Shi L, Wang B, Yang J, Xiao Z, Du P, et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev. 2017;58:1-13.
31
Radharani NNV, Yadav AS, Nimma R, Kumar TVS, Bulbule A, Chanukuppa V, et al. Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway. Cancer Cell Int. 2022;22:122.
32
Kim B, Seo Y, Kwon JH, Shin Y, Kim S, Park SJ, et al. IL-6 and IL-8, secreted by myofibroblasts in the tumor microenvironment, activate HES1 to expand the cancer stem cell population in early colorectal tumor. Mol Carcinog. 2021;60:188-200.
33
Liu Y, Gao Y, Lin T. Expression of interleukin-1 (IL-1), IL-6, and tumor necrosis factor-α (TNF-α) in non-small cell lung cancer and its relationship with the occurrence and prognosis of cancer pain. Ann Palliat Med. 2021;10:12759-66.
34
Yan X, Han L, Zhao R, Fatima S, Zhao L, Gao F. Prognosis value of IL-6, IL-8, and IL-1β in serum of patients with lung cancer: a fresh look at interleukins as a biomarker. Heliyon. 2022;8:e09953.
35
Guo J, Gao Y, Gong Z, Dong P, Mao Y, Li F, et al. Plasma D-dimer level correlates with age, metastasis, recurrence, tumor-node-metastasis classification (TNM), and treatment of non-small-cell lung cancer (NSCLC) Patients. Biomed Res Int. 2021;2021:9623571.
36
Xiao X, Wang S, Long G. C-reactive protein is a significant predictor of improved survival in patients with advanced non-small cell lung cancer. Medicine (Baltimore). 2019;98:e16238.
